Exhibit 99.2
Robert Glanzman, MD FAAN On behalf of REPAIR - MS Investigators Jimin Ren 1 , Austin Rynders 2 , Benjamin Greenberg 1 , Karen S. Ho 2 , Robert Glanzman 2 , Michael T. Hotchkin 2 1 University of Texas Southwestern Medical Center 2 Clene Nanomedicine, Inc. P 0 4 3 Effects of Nanocatalysis on CNS Bioenergetic Markers in Patients Treated with CNM - Au8: Interim Results from a Phase 2 31 Phosphorous Magnetic Resonance Imaging Study in Relapsing MS 1
Disclosures I am an employee of Clene Nanomedicine, Inc. and receive salary and stock options 2
C N M - Au8 | M o A : N a n o c a t a l y t i c E l e c t r o n T r a n s f e r 3
• Difference in average metabolites (e.g., NAD+, NADH) concentration at Week 12 - 16 • Difference in average brain membrane markers (PCr, PME, PE, etc.) at Week 12 - 16 • Pharmacodynamic biomarkers at Week 12 - 16 Change in Brain Bioenergetic Potential (NAD+/NADH) vs. Baseline Visit safety assessment dispense drug Visit safety assessment dispense drug Visit Pr i m a r y E n dp o i n t Visit Fo ll o w - up Visit ba s e li n e assessments dispense drug 1 ι 2 ι R E P A I R : P ha s e 2 3 1 P - M R S I m a g i n g A Phase 2 , Open Label, Sequential Group, Investigator Blinded Study of Magnetic Re sonance Sp e c t r o s c o p y ( 3 1 P - M R S ) t o A sse s s t h e E ff e c t s o f C N M - A u 8 f o r t h e B i o e n e r g e ti c I m p r o v e me n t of Impaired Neuronal R edox State in Relapsing MS + 4
REPAIR - MS | 3 1 P M R S Ima g i n g Mo d a l i t y A T P - - P C r G P E G P C PC PE Pi in Pi ex - NAD UD PG Full Volume Coil Partial Volume Coil Pi in - intracellular inorganic phosphate Pi ex - extracellular inorganic phosphate PC - phosphocholine PE - phosphoethanolamine GPE - glycerophosphoethanolamine GPC - glycerophosphocholine ATP - ࢻ , ATP - ࢼ , ATP - ࢽ NAD+/NADH (partial coil only) NAD Pool (Full coil) UDPG – uridine diphosphate glucose P C r – p h o s p h o c r e a t in e (normalization factor) Average change in Area Under Curve by 31P peak (per 2 cm 3 voxel, ~600 voxels per subject); normalized by PCr 5
REPAIR - MS Baseline Demographics 2 7 − J a nu a r y − 2 0 2 1 D a t a U p d a t e Ba s e li ne Values S u bje c ts n (%) Age [ y rs . ] mean (SD) EDSS m e an (SD) Time from MS Onset [yrs.] mean (SD) N ataliz um a b Treatment (%) All 9 (100%) 46.5 (10.8) 3.6 (2.3) 7.2 (5.0) 100% Female 7 39.7 3.0 6.5 100% (78%) (11.6) (2.2) (3.7) Male 2 48.5 3.8 11.3 100% (22%) (10.6) (3.9) (2.9) 6
REPAIR − MS | Percent Change in NAD + /NADH [Partial Volume Coil] CNM - Au8 Increases Brain NAD + /NADH Ratio 7
CNM - Au8 Normalizes Brain ATP Levels Correlation of % Change versus BL value by Subject for Ƒ − ATP & − ATP [Full Volume Coil] 8
CNM - Au8 Open Label (m)MSFC Clinical Data SDMT & 9HPT 9
Con cl u s io n s • Data demonstrate CNM - Au8 target engagement in brains of MS patients • Catalytic bioenergetic improvements demonstrated across key CNS metabolic markers - NAD+/NADH ratio - ATP ( ߙ , ߛ ) 10
